Welcome to our dedicated page for AC Immune SEC filings (Ticker: ACIU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The AC Immune SA (NASDAQ: ACIU) SEC filings page on Stock Titan provides centralized access to the company’s U.S. regulatory disclosures as a foreign private issuer. AC Immune files annual reports on Form 20-F and furnishes current reports on Form 6-K, which together offer insight into its clinical-stage biopharmaceutical operations focused on precision prevention of neurodegenerative diseases.
Through its 6-K submissions, AC Immune furnishes interim condensed consolidated financial statements prepared under IFRS, management’s discussion and analysis of financial condition and results of operations, and press releases covering clinical and corporate developments. Examples include reports on interim Phase 2 data for the anti-alpha-synuclein active immunotherapy ACI-7104.056 in Parkinson’s disease, strategic pipeline refocusing and workforce reductions, and quarterly cash position and loss figures.
Investors can use these filings to track how AC Immune funds and prioritizes its programs, including active immunotherapies such as ACI-24.060 and ACI-35.030, small-molecule candidates like the NLRP3 inhibitor ACI-19764, and diagnostic PET tracers such as ACI-19626 and ACI-15916. Governance-related filings, including annual general meeting results, board and committee elections, compensation approvals and auditor reappointments, are also furnished on Form 6-K and incorporated by reference into the company’s shelf registration statements.
On Stock Titan, these SEC documents are updated as they are filed with EDGAR, and AI-powered tools can help summarize lengthy 20-F and 6-K materials, highlight key risk factors, and surface important changes in clinical, financial or governance disclosures. This allows users to quickly understand how AC Immune’s regulatory reporting reflects the evolution of its neurodegeneration-focused pipeline and collaboration agreements.
AC Immune SA director Martin Zuegel filed an initial ownership report showing equity interests in the company. He holds share options over 52,577 and 32,061 common shares, each with an exercise price of $1.8400 per share and an expiration date of June 17, 2035. One option grant will fully vest on June 17, 2026, while the other will vest annually in three equal installments beginning on June 17, 2026. He also directly holds 38,272 common shares, which reflect common shares underlying outstanding restricted share units.
AC Immune SA Chief Operating Officer Piergiorgio Donati filed an initial ownership report detailing his equity position. He directly holds 141,120 common shares, which include 136,620 common shares underlying outstanding restricted share units. In addition, he reports multiple share options over common shares with exercise prices between $2.03 and $9.50 per share and expiration dates from July 2028 through December 2035. Some options are already fully vested, while others vest in twelve substantially equal quarterly installments beginning on March 31, 2024, March 31, 2025, and March 31, 2026, providing a staggered schedule of potential future share deliveries.
AC Immune SA’s Chief Financial Officer Christopher James Roberts has filed an initial statement of holdings. He reports direct ownership of 155,382 common shares, which the footnotes state includes 109,564 common shares underlying outstanding restricted share units. He also reports a series of share options to buy common shares with exercise prices ranging from 2.32 to 6.88 and expirations between 2029 and 2035. One option grant is fully vested, while others vest in twelve substantially equal quarterly installments beginning on March 31, 2024, March 31, 2025, and March 31, 2026.
AC Immune SA director Monika Buetler filed an initial statement of beneficial ownership, detailing existing share and option positions. She reports direct ownership of 53,905 common shares, which includes 52,905 common shares underlying outstanding restricted share units. This filing does not show new buying or selling activity.
Buetler also holds several share options over AC Immune common shares with different exercise prices and maturities. These include options over 14,310 shares at an exercise price of 5.3100 that are fully vested and expire on December 9, 2031, and options over 56,204 shares at an exercise price of 3.1500 expiring on June 23, 2032. She further holds options over 39,823 shares at 2.1500 expiring June 23, 2033, and 15,501 shares at 4.2300 expiring June 30, 2034. Another option covers 46,392 shares at 1.8400 and will fully vest on June 17, 2026, with expiration on June 17, 2035. Together, these positions describe her current equity-based exposure to AC Immune, rather than recent market transactions.
AC Immune SA director Roy Ervin Twyman reported his initial holdings on a Form 3. He directly holds 75,988 common shares, including 49,988 common shares underlying outstanding restricted share units. He also holds multiple share options over common shares with exercise prices between $1.84 and $7.23, expiring from 2029 through 2035.
According to the footnotes, at least one share option grant is fully vested and another will fully vest on June 17, 2026, highlighting a mix of already exercisable and time-based equity awards.
AC Immune SA director Renee Aguiar‑Lucander has filed an initial ownership report. The filing shows direct ownership of 34,568 Common Shares. She also holds two share option awards, each exercisable at $1.8400 per share and expiring on June 17, 2035, covering 43,299 and 32,061 underlying Common Shares.
According to the footnotes, the 43,299-share option will fully vest on June 17, 2026, while the 32,061-share option vests in three equal annual installments beginning on that same date. This Form 3 records her starting equity position as a director rather than reporting new market transactions.
AC Immune SA Chief Executive Officer Andrea Pfeifer filed an initial statement of beneficial ownership, reporting 3,840,288 Common Shares held directly and 14,000 Common Shares held indirectly by her spouse. The direct position includes 1,921,005 Common Shares underlying outstanding restricted share units.
The filing also lists several fully vested share options over Common Shares with exercise prices between 2.03 and 9.53 per share and expiration dates from 2027 through 2032, providing a detailed snapshot of the CEO’s current equity-based incentives.
AC Immune SA director June Carl Howard has filed an initial ownership report showing equity interests in the company. Howard directly holds 50,988 common shares, including 49,988 common shares underlying outstanding restricted share units. In addition, Howard holds several fully vested or time‑vesting share options to purchase common shares at exercise prices ranging from $1.84 to $7.23, with expiration dates between 2030 and 2035. This filing records existing positions and does not reflect any new share purchases or sales.
AC Immune reported full-year 2025 results, highlighting pipeline progress alongside a wider loss. Contract revenue fell to CHF 3.6m from CHF 27.3m, mainly as prior Janssen milestones rolled off, while the net loss widened to CHF 70.4m with a basic and diluted loss per share of CHF 0.70.
Cash and cash equivalents were CHF 26.8m and short-term financial assets CHF 64.6m as of December 31, 2025, and management prepared the accounts on a going-concern basis. The company emphasized positive interim VacSYn Phase 2 data for ACI-7104 in early Parkinson’s disease, a Phase 1 NLRP3 inhibitor (ACI-19764), and a sharpened pipeline focus supported by 2025 restructuring.
AC Immune is a Switzerland-based biopharmaceutical company focused on therapies and diagnostics for neurodegenerative diseases such as Alzheimer’s and Parkinson’s. It has no approved products and does not expect product revenue for several years, relying instead on R&D collaborations and funding.
The pipeline includes active immunotherapies ACI‑35.030, ACI‑24.060 and ACI‑7104.056, small molecule ACI‑19764 and Morphomer programs, and PET tracers PI‑2620, ACI‑12589, ACI‑15916 and ACI‑19626. Several assets have FDA Fast Track designation. Key partners include Eli Lilly, Janssen, Lantheus and Takeda.
The filing emphasizes extensive risks: clinical failure or delay, heavy dependence on partners, intense competition, IP and generic challenges, reimbursement pressures, ESG and climate rules, cybersecurity and data‑privacy exposure, pandemics, geopolitical shocks and new U.S. trade tariffs. As of the period end, 101,742,231 common shares were outstanding.